Press Releases
- 2022
-
July 6, 2022 June 27, 2022 Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
Learn MoreJune 16, 2022 Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
Learn MoreJune 1, 2022 Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Learn MoreMay 24, 2022 European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
Learn MoreMay 19, 2022 Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
Learn MoreJanuary 18, 2022 Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
Learn MoreJanuary 6, 2022 Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma
Learn More - 2021
-
December 13, 2021 Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition
Learn MoreNovember 11, 2021 Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma
Learn MoreNovember 3, 2021 European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt’s Lymphoma
Learn MoreOctober 28, 2021 Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Learn MoreSeptember 27, 2021 Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.
Learn MoreAugust 26, 2021 President and CEO of Rafael Pharmaceuticals, Sanjeev Luther, to Present at the 11th Annual World Orphan Drug Congress USA 2021
Learn MoreAugust 25, 2021 Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
Learn MoreJuly 1, 2021 Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn MoreJune 30, 2021 Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) Congress
Learn MoreJune 29, 2021 FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer
Learn MoreJune 23, 2021 Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021
Learn MoreMay 26, 2021 Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program
Learn MoreMarch 30, 2021 Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn MoreJanuary 19, 2021 Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
Learn MoreJanuary 13, 2021 Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
Learn More - 2020
-
December 15, 2020 Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
Learn MoreDecember 1, 2020 Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue
Learn MoreNovember 10, 2020 Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
Learn MoreOctober 29, 2020 FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma
Learn MoreOctober 27, 2020 Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn MoreOctober 20, 2020 A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613®️ (devimistat) for Patients With Pancreatic Cancer in Japan
Learn MoreAugust 6, 2020 Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
Learn MoreJuly 21, 2020 Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn MoreMay 26, 2020 Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Learn MoreMay 7, 2020 Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models
Learn MoreMay 5, 2020 Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer
Learn MoreApril 28, 2020 MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia
Learn MoreApril 23, 2020 Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn MoreMarch 24, 2020 Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ️ (devimistat) for Patients with Metastatic Pancreatic Cancer
Learn MoreMarch 3, 2020 Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer
Learn MoreJanuary 21, 2020 Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer.
Learn MoreJanuary 14, 2020 Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
Learn MoreJanuary 13, 2020 Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
Learn More - 2019
-
December 18, 2019 Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either relapsed/refractory Burkitt lymphoma/leukemia or high-grade B-cell lymphoma at OncLive TV.
Learn MoreDecember 3, 2019 Data on Rafael Pharmaceuticals’ CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition
Learn MoreDecember 3, 2019 Timothy Pardee, M.D., Ph.D., Co-Chief Medical Officer of Rafael Pharmaceuticals, to Present on CPI-613® (devimistat) in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposistion
Learn MoreDecember 2, 2019 Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt’s Lymphoma/Leukemia to Massachusetts General Hospital in Boston
Learn MoreNovember 7, 2019 Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership
Learn MoreOctober 30, 2019 Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D.
Learn MoreOctober 28, 2019 Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn MoreOctober 24, 2019 Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer
Learn MoreOctober 17, 2019 Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
Learn MoreOctober 8, 2019 Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
Learn MoreOctober 8, 2019 Rafael Pharmaceuticals Congratulates Scientific Advisory Board Member Gregg L. Semenza For Receiving 2019 Nobel Prize in Medicine
Learn MoreOctober 2, 2019 Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer
Learn MoreSeptember 19, 2019 Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn MoreSeptember 17, 2019 Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
Learn MoreSeptember 16, 2019 Peer-Reviewed Journal Future Oncology Publishes Two Manuscripts on Cancer Metabolism and Drug Candidate CPI-613® (Devimistat)
Learn MoreAugust 1, 2019 Rafael Pharmaceuticals Announces Expansion into Austria, South Korea and Spain of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn MoreJuly 18, 2019 Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
Learn MoreJune 25, 2019 Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries
Learn MoreJune 6, 2019 Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, Named Finalist for The 2019 EY Entrepreneur Of The Year® Award in New Jersey
Learn MoreJune 4, 2019 Rafael Pharmaceuticals to Present at the 2019 Jefferies Global Healthcare Conference
Learn MoreMay 16, 2019 Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala
Learn MoreMay 13, 2019 Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations
Learn MoreFebruary 7, 2019 CPI-613® (devimistat) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”
Learn MoreJanuary 17, 2019 Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium
Learn MoreJanuary 10, 2019 EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (devimistat) for Treatment of Metastatic Pancreatic Cancer
Learn MoreJanuary 10, 2019 EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (devimistat) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn MoreJanuary 9, 2019 Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613® for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
Learn MoreJanuary 9, 2019 Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613® in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Learn MoreJanuary 7, 2019 Rafael Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Learn More - 2018
-
December 11, 2018 Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer
Learn MoreNovember 29, 2018 Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Learn MoreNovember 6, 2018 Rafael Pharmaceuticals Appoints Vice President, Manufacturing and CMC Regulatory Affairs and Vice President of Regulatory Affairs to Strengthen Development of CPI-613®
Learn MoreOctober 9, 2018 Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
Learn MoreAugust 16, 2018 Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613® for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Learn MoreAugust 13, 2018 Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613® in Patients with Relapsed or Refractory T-Cell Lymphoma
Learn MoreJuly 13, 2018 Rafael Pharmaceuticals Appoints Two Prominent Gastrointestinal Oncologists from Europe to its Medical Advisory Board to Support Global Development of CPI-613® in Pancreatic Cancer and Other Gastrointestinal Malignancies
Learn MoreJune 28, 2018 Rafael Pharmaceuticals Receives FDA Orphan Drug Designation for Treatment of Burkitt Lymphoma, and Initiates a Phase II Clinical Trial of CPI-613® for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
Learn MoreJune 14, 2018 Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613® in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association
Learn MoreJune 4, 2018 Rafael Pharmaceuticals to Present at 2018 Bio International Conference
Learn MoreApril 12, 2018 Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals’ Lead CPI-613® Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
Learn More - 2017
-
December 7, 2017 Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613® in Treating Acute Myeloid Leukemia at the 2017 American Society of Hematology Annual Meeting & Exposition
Learn MoreNovember 16, 2017 Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613® in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer
Learn MoreSeptember 8, 2017 Rafael Pharmaceuticals to Present Late Breaking Data at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
Learn MoreJune 19, 2017 Rafael Pharmaceuticals to Present at 2017 BIO International Convention
Learn MoreJune 5, 2017 Cornerstone Pharmaceuticals, Inc. Announces Corporate Name Change to Rafael Pharmaceuticals, Inc.
Learn MoreMay 22, 2017 Rafael Pharmaceuticals to Present at the BioNJ 7th Annual BioPartnering Conference, May 23, 2017
Learn MoreMay 9, 2017 The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Rafael Pharmaceuticals’ CPI-613® in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
Learn MoreMarch 23, 2017 FDA Provides Rafael Pharmaceuticals Approval to Initiate Pivotal Study for CPI-613®, its Metabolism-Directed Anticancer Compound
Learn MoreFebruary 8, 2017 Rafael Pharmaceuticals, Inc. Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards
Learn MoreJanuary 10, 2017 Rafael Pharmaceuticals, Inc. Announces Additions to its Board of Directors: Jean-Pierre Sommadossi, Ph.D., Richard Axel, M.D., Chi Van Dang, M.D., Ph.D., and Richard Scheller, Ph.D.
Learn More - 2016
-
December 22, 2016 Rafael Pharmaceuticals to Present at 9th Annual Biotech Showcase™ in San Francisco, January 9-11, 2017
Learn MoreDecember 5, 2016 Rafael Pharmaceuticals, Inc. Presents Phase I Data on CPI-613® in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin’s Lymphoma (T-cell NHL) at ASH 2016
Learn MoreNovember 29, 2016 Rafael Pharmaceuticals Appoints Brian Mullaney, M.D., Ph.D., as Chief Medical Officer
Learn MoreNovember 21, 2016 Rafael Pharmaceuticals to Present New Data on CPI-613® at the American Society of Hematology 2016 Annual Meeting
Learn MoreNovember 10, 2016 IDT Corporation Announces Investment in Rafael Pharmaceuticals
Learn MoreOctober 6, 2016 Rafael Pharmaceuticals Announces Acceptance of Abstract on CPI-613® Pancreatic Cancer Trial by European Society for Medical Oncology (ESMO) Congress 2016
Learn MoreSeptember 26, 2016 Rafael Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016
Learn MoreFebruary 5, 2016 Rafael Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016
Learn MoreJanuary 22, 2016 Phase I Trial Data for Rafael Pharmaceuticals’ CPI-613® in Combination with Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin (mFOLFIRINOX) in Metastatic Pancreatic Adenocarcinoma to Be Presented at the Annual Gastrointestinal Cancers Symposium
Learn More - 2015
-
November 23, 2015 Phase I Trial Data for Rafael Pharmaceuticals’ CPI-613® in Combination with High Dose Ara-C (HDAC) and Mitoxantrone in Relapsed or Refractory Acute Myeloid Leukemia to Be Presented at 57th Annual ASH Meeting
Learn MoreJanuary 21, 2015 Rafael Pharmaceuticals Receives Funding through New Jersey’s Technology Business Tax Certificate Transfer Program
Learn MoreJanuary 12, 2015 Rafael Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613® for the Treatment of Metastatic Colorectal Cancer
Learn More - 2014
-
December 5, 2014 Rafael Pharmaceuticals Commences Phase I Clinical Trial of CPI-613® for the Treatment of B-Cell Non-Hodgkin Lymphoma
Learn MoreNovember 13, 2014 Rafael Pharmaceuticals’ CPI-613® Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting Oncology Projects to Watch
Learn MoreNovember 6, 2014 Rafael Pharmaceuticals Announces Positive Phase I Data for CPI-613® in Relapsed or Refractory AML Patients to be Presented at 2014 ASH Annual Meeting
Learn MoreOctober 21, 2014 Rafael Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613® for the Treatment of Hodgkin’s or T-Cell Non-Hodgkin’s Lymphoma
Learn MoreOctober 9, 2014 Rafael Pharmaceuticals Appoints Steve Carchedi Chief Executive Officer
Learn MoreOctober 7, 2014 Rafael Pharmaceuticals’ CPI-613® Phase I Hematologic Malignancies Trial Data Published in AACR’s Clinical Cancer Research
Learn MoreMay 14, 2014 Rafael Pharmaceuticals Clinical Data on CPI-613® to be Presented at ASCO 2014
Learn MoreApril 18, 2014 Rafael Pharmaceuticals’ CPI-613® Data to be Presented at the 2014 Annual American Society of Clinical Oncology (ASCO) Meeting
Learn MoreMarch 12, 2014 Rafael Pharmaceuticals Lead Compound CPI-613® Demonstrates Ability to Disrupt Growth of Cancer Cells
Learn MoreFebruary 28, 2014 Rafael Pharmaceuticals Presents Non-Small Cell Lung Cancer Data for CPI-613® at 2014 Special Conference of American Association for Cancer Research
Learn MoreJanuary 31, 2014 Rafael Pharmaceuticals Appoints Dr. Chi Van Dang to Scientific Advisory Board
Learn More - 2013
-
December 9, 2013 Rafael Pharmaceuticals Presents Updated Phase I Data for CPI-613® at 2013 American Society of Hematology Annual Meeting
Learn MoreNovember 13, 2013 Rafael Pharmaceuticals to Present on Cancer Metabolism at Target TME 2013 Workshop
Learn MoreNovember 11, 2013 Rafael Pharmaceuticals to Present CPI-613® Phase I Results at 2013 American Society of Hematology Annual Meeting
Learn MoreOctober 31, 2013 Rafael Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613® in Patients with Locally Advanced or Metastatic Pancreatic Cancer
Learn MoreOctober 24, 2013 Rafael Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613® for the Treatment of Small Cell Lung Cancer
Learn MoreOctober 3, 2013 Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613® for Treatment of Myelodysplastic Syndrome
Learn MoreSeptember 25, 2013 Rafael Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613® for the Treatment of Myelodysplastic Syndrome
Learn MoreAugust 30, 2013 Rafael Pharmaceuticals Appoints Dr. Sim Fass and Howard Jonas to Board of Directors
Learn MoreAugust 12, 2013 Rafael Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613® for the Treatment of Acute Myelogenous Leukemia
Learn MoreAugust 8, 2013 Rafael Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613® for the Treatment of Advanced Bile Duct Cancers
Learn MoreJune 3, 2013 Rafael Pharmaceuticals Presents Data at 2013 Annual ASCO Meeting
Learn MoreMay 23, 2013 Rafael Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613® in Patients with Advanced Solid Tumors
Learn MoreApril 22, 2013 Rafael Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613® with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
Learn More - 2012
-
September 28, 2012 Rafael Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at the Tenth Annual Discovery On Target Conference in Boston regarding cancer cell metabolism
Learn MoreSeptember 24, 2012 Rafael Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at BioX 2012 Conference
Learn MoreJune 1, 2012 Rafael Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613® at 2012 Annual ASCO Meeting
Learn MoreApril 30, 2012 Rafael Pharmaceuticals announces publication of case report on treatment of a patient presenting metastatic pancreatic cancer with CPI-613 and gemcitabine combination therapy
Learn MoreApril 2, 2012 Rafael Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613® at 2012 Annual AACR Meeting
Learn More - 2011
-
December 12, 2011 Rafael Pharmaceuticals’ cancer metabolism inhibitor, CPI-613®, showing promise in Phase I trial for acute myeloid leukemia
Learn MoreOctober 26, 2011 Rafael Pharmaceuticals to present at the 9th Annual Discovery on Target Meetings in Boston
Learn MoreSeptember 15, 2011 Rafael Pharmaceuticals publishes positive pre-clinical study results comparing its proprietary drug EmPAC™ to Taxol® in the Journal of Nanoscience and Nanotechnology
Learn MoreSeptember 6, 2011 Rafael Pharmaceuticals announces FDA orphan drug designation of CPI-613® for patients with acute myeloid leukemia
Learn MoreJuly 25, 2011 Rafael Pharmaceuticals announces the Journal of Molecular Medicine’s publication of research showing selective inhibition of cancer cell energy metabolism with its novel lipoate derivative compounds
Learn MoreJune 3, 2011 Wake Forest Baptist Medical Center and Rafael Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613® in Acute Myeloid Leukemia
Learn MoreMarch 14, 2011 Rafael Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
Learn More - 2010
-
November 5, 2010 Rafael Pharmaceuticals Awarded $490K in Grants Under QTDP Program
Learn MoreOctober 11, 2010 Rafael Pharmaceuticals Presents Interim Phase I Data at the European Society of Medical Oncology Annual Conference
Learn MoreSeptember 9, 2010 Dr. Robert Shorr, Leading Scientist in Cancer Metabolism, to Speak at Two Upcoming Pharmaceutical Conferences
Learn MoreAugust 17, 2010 Rafael Pharmaceuticals Appoints Dr. Dorit Arad Director of Research and Development for its Israeli Operations
Learn MoreAugust 5, 2010 Rafael Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First-in-Class Anti-Cancer Agent CPI-613®
Learn MoreJune 7, 2010 Rafael Pharmaceuticals Appoints Timothy Sullivan Executive Vice President and Head of Corporate Development
Learn MoreApril 19, 2010 Rafael Pharmaceuticals Partners with Wake Forest University on Clinical Trial of CP-613® for Hematologic Malignancies
Learn MoreMarch 22, 2010 Rafael Pharmaceuticals Enters Into a Collaboration Agreement with the U.S. National Cancer Institute
Learn MoreMarch 8, 2010 Dr. Robert Shepard Appointed Chief Medical Officer for Rafael Pharmaceuticals
Learn MoreFebruary 8, 2010 Rafael Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First- In-Class Anti-Cancer Agent CPI-613®
Learn More - 2009
-
November 11, 2009 Rafael Pharmaceuticals Chosen Among Top 10 Most Interesting Oncology Projects
Learn MoreNovember 4, 2009 Leading Oncologist Dr. Robert Shepard Joins Rafael Pharmaceuticals as Acting Chief Medical Officer
Learn MoreOctober 5, 2009 Rafael Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D., to its Scientific Advisory Board
Learn MoreMay 27, 2009 Rafael Pharmaceuticals Initiates Phase I/II Combination Therapy Clinical Trial of CPI-613® for Treatment of Pancreatic Cancer
Learn MoreMay 27, 2009 Rafael Pharmaceuticals Announces $6M Financing to Further Advance Clinical Trials in Cancer Patients
Learn More - 2008
-
September 24, 2008 Rafael Pharmaceuticals Announces Initiation of Clinical Trials of CPI-613® for the Treatment of Cancer
Learn MoreJuly 24, 2008 Rafael Pharmaceuticals Announces Approval to Conduct Phase I / II Clinical Trial of CPI-613® in Cancer Patients by US FDA
Learn More